Patents Assigned to PRECEDO PHARMACEUTICALS CO., LTD
-
Publication number: 20230235283Abstract: Provided are a primary cell culture medium that contains a combination of an MST1/2 kinase inhibitor and a ROCK kinase inhibitor and is used for culturing primary esophageal squamous cell carcinoma epithelial cells, and a culture method using the primay cell culture medium. In the culture method, the primary cell culture medium is used to culture primay cells on a culture vessel coated with an extracellular matrix glue, so that the primary cells prolilferate rapidly. A cell model obtained by using the primary cell culture medium and the primary cell culture method of the present invention can be used for the efficacy evaluation and screening of drugs.Type: ApplicationFiled: April 23, 2020Publication date: July 27, 2023Applicant: PRECEDO PHARMACEUTICALS CO., LTDInventors: Qingsong LIU, Jie HU, Wenchao WANG, Cheng CHEN, Tao REN, Li WANG
-
Publication number: 20230091960Abstract: Provided are a culture medium and cultivation method of rapidly expanding primary cells of esophageal squamous carcinoma in vitro, and the use thereof in screening drugs. The culture medium comprises an initial culture medium selected from DMEM/F12, DMEM, F12, or RPMI-1640, a Rho protease inhibitor, an antibiotic, insulin, an N2 additive, insulin-like growth factor 1, a non-essential amino acid, and optionally, hydrocortisone, optionally, glutamine, and optionally, bovine pituitary extract.Type: ApplicationFiled: February 26, 2020Publication date: March 23, 2023Applicant: PRECEDO PHARMACEUTICALS CO., LTDInventors: Qingsong LIU, Jie HU, Cheng CHEN, Wenchao WANG, Li WANG
-
Publication number: 20220389379Abstract: Provided is a culture medium containing amphiregulin for culturing primary breast epithelial cells and a culture method involving using the medium. In the culturing method, primary cells are cultured on a culture vessel coated with an extracellular matrix gel by using the culture medium, and the primary cells grow on the culture vessel, which has been coated with the extracellular matrix gel, and proliferate rapidly under the combined action of nutrient factors and an extracellular matrix contained in the primary cell culture medium. The cell model obtained by the primary cell culture medium and the primary cell culture method can be used for the evaluating the efficacy of and screening drugs.Type: ApplicationFiled: November 18, 2019Publication date: December 8, 2022Applicant: PRECEDO PHARMACEUTICALS CO., LTDInventors: Qingsong LIU, Feiyang LIU, Husheng MEI, Wenchao WANG, Ming ZHAO, Zongru JIANG, Tao REN, Li WANG
-
Patent number: 10975082Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).Type: GrantFiled: June 5, 2017Date of Patent: April 13, 2021Assignee: PRECEDO PHARMACEUTICALS CO., LTDInventors: Qingsong Liu, Jing Liu, Xixiang Li, Aoli Wang, Ziping Qi, Hong Wu, Jiaxin Wu, Wenchao Wang, Chen Hu, Cheng Chen, Li Wang, Beilei Wang
-
Patent number: 10793543Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.Type: GrantFiled: March 28, 2017Date of Patent: October 6, 2020Assignees: PRECEDO PHARMACEUTICALS CO., LTD, HEFEI GRACEVO BIO-MEDICINE CO., LTDInventors: Qingsong Liu, Jing Liu, Qiang Wang, Beilei Wang, Feiyang Liu, Shuang Qi, Ziping Qi, Fengming Zou, Cheng Chen, Wenchao Wang, Chen Hu, Xiaochuan Liu, Wei Wang, Aoli Wang, Li Wang, Zhenquan Hu, Tao Ren
-
Patent number: 10781214Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.Type: GrantFiled: December 27, 2016Date of Patent: September 22, 2020Assignee: PRECEDO PHARMACEUTICALS CO., LTD.Inventors: Qingsong Liu, Jing Liu, Xixiang Li, Aoli Wang, Hong Wu, Kailin Yu, Chen Hu, Wenchao Wang, Cheng Chen, Fengming Zou, Ziping Qi, Li Wang, Beilei Wang
-
Publication number: 20200010471Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).Type: ApplicationFiled: June 5, 2017Publication date: January 9, 2020Applicant: PRECEDO PHARMACEUTICALS CO., LTDInventors: Qingsong LIU, Jing LIU, Xixiang LI, Aoli WANG, Ziping QI, Hong WU, Jiaxin WU, Wenchao WANG, Chen HU, Cheng CHEN, Li WANG, Beilei WANG
-
Patent number: 10350210Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.Type: GrantFiled: December 15, 2016Date of Patent: July 16, 2019Assignee: PRECEDO PHARMACEUTICALS CO., LTDInventors: Jing Liu, Qingsong Liu, Taoshan Jiang, Aoli Wang, Jiaxin Wu, Hong Wu, Ziping Qi, Yongfei Chen, Fengming Zou, Wenchao Wang, Zheng Zhao, Li Wang, Beilei Wang
-
Publication number: 20190084960Abstract: The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.Type: ApplicationFiled: March 28, 2017Publication date: March 21, 2019Applicants: PRECEDO PHARMACEUTICALS CO., LTD, HEFEI GRACEVO BIO-MEDICINE CO., LTDInventors: Qingsong LIU, Jing LIU, Qiang WANG, Beilei WANG, Feiyang LIU, Shuang QI, Ziping QI, Fengming ZOU, Cheng CHEN, Wenchao WANG, Chen HU, Xiaochuan LIU, Wei WANG, Aoli WANG, Li WANG, Zhenquan HU, Tao REN
-
Publication number: 20190010159Abstract: The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.Type: ApplicationFiled: December 27, 2016Publication date: January 10, 2019Applicant: PRECEDO PHARMACEUTICALS CO., LTDInventors: Qingsong LIU, Jing LIU, Xixiang LI, Aoli WANG, Hong WU, Kailin YU, Chen HU, Wenchao WANG, Cheng CHEN, Fengming ZOU, Ziping QI, Li WANG, Beilei WANG
-
Publication number: 20180369242Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.Type: ApplicationFiled: December 15, 2016Publication date: December 27, 2018Applicant: PRECEDO PHARMACEUTICALS CO., LTDInventors: Jing LIU, Qingsong LIU, Taoshan JIANG, Aoli WANG, Jiaxin WU, Hong WU, Ziping QI, Yongfei CHEN, Fengming ZOU, Wenchao WANG, Zheng ZHAO, Li WANG, Beilei WANG